TD Cowen raised the firm’s price target on Insmed to $98 from $75 and keeps a Buy rating on the shares. The firm noted they updated guidance on timing of data readouts; NDA filing for brenso in NCFBE is due in 4Q24 with US launch in mid-25 EU/JP in 1H26. Topline data for both the Ph2b PAH TPIP trial and Ph2 CRSsNP brenso trial are due 2H25.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: